Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant: SMC2846

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Glofitamab in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory DLBCL who are ineligible for ASCT is being assessed for use by NHSScotland (SMC2846).

The aim of this work was to capture real-world evidence from Scotland on the use of Systemic Anti-Cancer Therapy (SACT) for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are ineligible for autologous stem cell transplant (ASCT). Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2846, to patients in Scotland.

The objectives were to:

• Determine the number of patients prescribed first SACT for relapsed or refractory DLBCL who are ineligible for ASCT.
• Describe the baseline characteristics of patients prescribed first SACT for relapsed or refractory DLBCL who are ineligible for ASCT.
• Describe treatment characteristics for first SACT treatment of relapsed or refractory DLBCL in patients who are ineligible for ASCT.